ストックスクリーナーアプリを入手
101.19
0.70%
0.70
アフターアワーズ：
101.19
Revolution Medicines Inc (RVMD) 最新ニュース
Handelsbanken Fonder AB Grows Position in Revolution Medicines, Inc. $RVMD - MarketBeat
Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 30,000 Shares - MarketBeat
Revolution Medicines director Goldsmith sells shares worth $3.64 million - Investing.com
RVMD (RVMD) insider Goldsmith grants, exercises options and sells 36,000 shares - Stock Titan
Revolution Medicines (RVMD) grants CFO new stock and option awards - Stock Titan
Revolution Medicines (RVMD) COO awarded new stock and option grants - Stock Titan
Revolution Medicines at TD Cowen Conference: Strategic Insights on Cancer Trials - Investing.com Australia
Revolution Medicines, Inc. $RVMD Shares Purchased by Legato Capital Management LLC - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
RVMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Revolution Medicines Doubles Down on Costly RAS Push - TipRanks
Broker proposes sale of 3,000 RVMD shares (NASDAQ: RVMD) — Form 144 - Stock Titan
Mark A. Goldsmith sells 15,394 shares (RVMD) via Form 144 - Stock Titan
Insider Form 144: 30,000-share option transaction for RVMD (RVMD) - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: Navigating the Highs of a 27% Potential Upside - DirectorsTalk Interviews
Revolution Medicines, Inc. $RVMD Shares Bought by Rafferty Asset Management LLC - MarketBeat
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs - Insider Monkey
Can Revolution Medicines Inc outperform in the next rallyWeekly Volume Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Bought by TD Asset Management Inc - MarketBeat
UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating - marketscreener.com
Is RVMD’s Big Losses and Massive Equity Plans Reshaping the Investment Case for Revolution Medicines (RVMD)? - Yahoo Finance
Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Coverage Initiated at UBS Group - MarketBeat
Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating - marketscreener.com
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here’s Why - Insider Monkey
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform RatingHere's Why - Bitget
RVMD Sees Target Price Uplift from Piper Sandler Analyst | RVMD Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Wells Fargo & Company Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $144.00 - MarketBeat
RVMD: Wells Fargo Raises Price Target to $144 with Overweight Ra - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Shares Gap Down on Disappointing Earnings - MarketBeat
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View - Finviz
Piper Sandler raises Revolution stock price target on drug confidence By Investing.com - Investing.com Nigeria
Revolution Medicines (NASDAQ:RVMD) Given New $145.00 Price Target at Needham & Company LLC - MarketBeat
Westfield Capital Management Co. LP Buys 864,563 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Analyst Maintains "Buy" Rating but Lowers Price Target for RVMD - GuruFocus
Revolution Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? - Yahoo Finance
Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Upgraded by Evercore to Strong-Buy Rating - MarketBeat
Revolution Medicines Q4 Earnings Call Highlights - MarketBeat
Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc files for common stock offering of up to $1.0 billion - marketscreener.com
Revolution Medicines Q4 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines (RVMD) Advances Pipeline with Strong Financ - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings Results - MarketBeat
Revolution Medicines (RVMD) Earnings Transcript - AOL.com
Revolution Medicines Inc Files For Common Stock Offering Of Up To $1.0 Billion - TradingView
Earnings call transcript: Revolution Medicines Q4 2025 reveals strategic growth - Investing.com
Revolution Medicines (RVMD) Advances Clinical Progress in Cancer Treatments - GuruFocus
Revolution Medicines (RVMD) Projects Significant Operating Expen - GuruFocus
Revolution Medicines Q4 Loss Widens - marketscreener.com
Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss - marketscreener.com
Revolution Medicines Q4 net loss widens - TradingView
Revolution Medicines (RVMD) details RAS-targeted cancer drug pipeline - Stock Titan
Revolution Medicines, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
BRIEF-Revolution Medicines Q4 EPS USD -1.86 - TradingView
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - ChartMill
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - The Motley Fool
Revolution Medicines in spotlight as earnings loom after M&A chatter - Investing.com
Revolution Medicines in spotlight as earnings loom after M&A chatter By Investing.com - Investing.com UK
Revolution Medicines Q4 2025 earnings preview - MSN
Momentum Shift: Is now the right time to enter Revolution Medicines IncJuly 2025 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference - The Manila Times
Is Revolution Medicines (RVMD) Share Price Lagging Behind Its Long Term Surge? - Yahoo Finance
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):